Are polymorphisms in oestrogen receptors genes associated with lipid levels in response to hormone therapy?

References

• Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–613.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, et al.; Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Herrington DM, Klein KP. Invited review: Pharmacogenetics of estrogen replacement therapy. J Appl Physiol 2001;91:2776–2784.
   PubMed Web of Science ®Google Scholar
• Herrington DM. Hormone replacement therapy and heart disease: replacing dogma with data. Circulation 2003;107:2–4.
   PubMed Web of Science ®Google Scholar
• Casanova G, Radavelli S, Lhullier F, Spritzer PM. Effects of nonoral estradiol-micronized progesterone or low-dose oral estradiol-drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopause. Fertil Steril 2009;92:605–612.
   PubMed Web of Science ®Google Scholar
• Foryst-Ludwig A, Kintscher U. Metabolic impact of estrogen signalling through ERalpha and ERbeta. J Steroid Biochem Mol Biol 2010;122:74–81.
   PubMed Web of Science ®Google Scholar
• The NCBI’s SNP database [Internet]. U. S. National Library of Medicine, National Institutes of Health 2011 July – [cited 2011 May 18]. Available from http://www.ncbi.nlm.nih.gov/pubmed/gene
   Google Scholar
• Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Brosnihan KB, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002;346:967–974.
   PubMed Web of Science ®Google Scholar
• Lehtimäki T, Dastidar P, Jokela H, Koivula T, Lehtinen S, Ehnholm C, Punnonen R. Effect of long-term hormone replacement therapy on atherosclerosis progression in postmenopausal women relates to functional apolipoprotein e genotype. J Clin Endocrinol Metab 2002;87:4147–4153.
   PubMed Web of Science ®Google Scholar
• Koivu TA, Fan YM, Mattila KM, Dastidar P, Jokela H, Nikkari ST, Kunnas T, et al. The effect of hormone replacement therapy on atherosclerotic severity in relation to ESR1 genotype in postmenopausal women. Maturitas 2003;44:29–38.
   PubMed Web of Science ®Google Scholar
• Nordström P, Glader CA, Dahlén G, Birgander LS, Lorentzon R, Waldenström A, Lorentzon M. Oestrogen receptor alpha gene polymorphism is related to aortic valve sclerosis in postmenopausal women. J Intern Med 2003;254:140–146.
   PubMed Web of Science ®Google Scholar
• Shearman AM, Cupples LA, Demissie S, Peter I, Schmid CH, Karas RH, Mendelsohn ME, et al. Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA 2003;290:2263–2270.
   PubMed Web of Science ®Google Scholar
• Demissie S, Cupples LA, Shearman AM, Gruenthal KM, Peter I, Schmid CH, Karas RH, et al. Estrogen receptor-alpha variants are associated with lipoprotein size distribution and particle levels in women: the Framingham Heart Study. Atherosclerosis 2006;185:210–218.
   PubMed Web of Science ®Google Scholar
• Emre A, Sahin S, Erzik C, Nurkalem Z, Oz D, Cirakoglu B, Yesilcimen K, Ersek B. Effect of hormone replacement therapy on plasma lipoproteins and apolipoproteins, endothelial function and myocardial perfusion in postmenopausal women with estrogen receptor-alpha IVS1-397 C/C genotype and established coronary artery disease. Cardiology 2006;106:44–50.
   PubMed Web of Science ®Google Scholar
• Sowers MR, Symons JP, Jannausch ML, Chu J, Kardia SR. Sex steroid hormone polymorphisms, high-density lipoprotein cholesterol, and apolipoprotein A-1 from the Study of Women’s Health Across the Nation (SWAN). Am J Med 2006;119:S61–S68.
   Web of Science ®Google Scholar
• Alevizaki M, Saltiki K, Cimponeriu A, Kanakakis I, Xita N, Alevizaki CC, Georgiou I, Sarika HL. Severity of cardiovascular disease in postmenopausal women: associations with common estrogen receptor alpha polymorphic variants. Eur J Endocrinol 2007;156:489–496.
   PubMed Web of Science ®Google Scholar
• Molvarec A, Nagy B, Kovács M, Walentin S, Imreh E, Rigó J Jr, Szalay J, et al. Lipid, haemostatic and inflammatory variables in relation to the estrogen receptor alpha (ESR1) PvuII and XbaI gene polymorphisms. Clin Chim Acta 2007;380:157–164.
   PubMed Web of Science ®Google Scholar
• Klos KL, Boerwinkle E, Ferrell RE, Turner ST, Morrison AC. ESR1 polymorphism is associated with plasma lipid and apolipoprotein levels in Caucasians of the Rochester Family Heart Study. J Lipid Res 2008;49:1701–1706.
   PubMed Web of Science ®Google Scholar
• Nogueira-de-Souza NC, Guerreiro da Silva ID, Carvalho CV, Pulchinelli A, Haidar MA, Baracat EC, Massad-Costa AM. Effect of estrogen receptor-alpha (ESR1) gene polymorphism on high density lipoprotein levels in response to hormone replacement therapy. Braz J Med Biol Res 2009;42:1138–1142.
   PubMed Web of Science ®Google Scholar
• Lamon-Fava S, Herrington DM, Horvath KV, Schaefer EJ, Asztalos BF. Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status. Metab Clin Exp 2010;59:1794–1800.
   PubMed Web of Science ®Google Scholar
• Roszkowska-Gancarz M, Kurylowicz A, Polosak J, Ambroziak M, Puzianowska-Kuznicka M. The -351A/G polymorphism of ESR1 is associated with risk of myocardial infarction but not with extreme longevity. Clin Chim Acta 2010;411:1883–1887.
   PubMed Web of Science ®Google Scholar
• Zhao T, Zhang D, Liu Y, Zhou D, Chen Z, Yang Y, Li S, et al. Association between ESR1 and ESR2 gene polymorphisms and hyperlipidemia in Chinese Han postmenopausal women. J Hum Genet 2010;55:50–54.
   PubMed Web of Science ®Google Scholar
• Almeida S, Fiegenbaum M, de Andrade FM, Osório-Wender MC, Hutz MH. ESR1 and APOE gene polymorphisms, serum lipids, and hormonal replacement therapy. Maturitas 2006;54:119–126.
   PubMed Web of Science ®Google Scholar
• Almeida S, Franken N, Zandoná MR, Osório-Wender MC, Hutz MH. Estrogen receptor 2 and progesterone receptor gene polymorphisms and lipid levels in women with different hormonal status. Pharmacogenomics J 2005;5:30–34.
   PubMed Web of Science ®Google Scholar
• Nikkari ST, Henttonen A, Kunnas T, Kähönen M, Hutri-Kähönen N, Juonala M, Marniemi J, et al. Estrogen receptor 2 polymorphism and carotid intima-media thickness. Genet Test 2008;12:537–540.
   PubMedGoogle Scholar
• Silvestri S, Thomsen AB, Gozzini A, Bagger Y, Christiansen C, Brandi ML. Estrogen receptor alpha and beta polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy? Menopause 2006;13:451–461.
   PubMed Web of Science ®Google Scholar
• Saltiki K, Mantzou E, Doukas C, Kanakakis I, Zotos P, Lazaros L, Georgiou I, Alevizaki M. Estrogen receptor beta gene variants may be associated with more favorable metabolic profile in postmenopausal women undergoing coronary angiography. Exp Clin Endocrinol Diabetes 2009;117:610–615.
   PubMed Web of Science ®Google Scholar
• Almeida S, Hutz MH. Genetic variation of estrogen metabolism and the risks of cardiovascular disease. Curr Opin Investig Drugs 2007;8:814–820.
   PubMedGoogle Scholar
• Almeida S, Zandoná MR, Franken N, Callegari-Jacques SM, Osório-Wender MC, Hutz MH. Estrogen-metabolizing gene polymorphisms and lipid levels in women with different hormonal status. Pharmacogenomics J 2005;5:346–351.
   PubMed Web of Science ®Google Scholar
• Smiderle L, Galvão AC, Fontana C, Wender MC, Agnes G, Giovenardi M, Hutz MH, Almeida S. Evaluation of UGT1A1 and SULT1A1 polymorphisms with lipid levels in women with different hormonal status. Gynecol Endocrinol 2011;27:20–26.
   PubMed Web of Science ®Google Scholar
• Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 2003;100:177–182.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Lahiri DK, Nurnberger JI Jr.A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991;19:5444.
   PubMed Web of Science ®Google Scholar
• Long JC, Williams RC, Urbanek M. An E-M algorithm and testing strategy for multiple-locus haplotypes. Am J Hum Genet 1995;56:799–810.
   PubMed Web of Science ®Google Scholar
• Excoffier L, Laval G, Schneider S. Arlequin (version 3.0): an integrated software package for population genetics data analysis. Evol Bioinform Online 2005;1:47–50.
   PubMed Web of Science ®Google Scholar
• Lewontin RC. On measures of gametic disequilibrium. Genetics 1988;120:849–852.
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B 1995;57:289–300.
   Google Scholar
• Abramson JH, Gahlinger PM: Computer Programs for Epidemiologists: PEPI V.4.0. Salt Lake City, Utah: Sagebrush Press; 2001.
   Google Scholar
• Nilsson M, Dahlman I, Jiao H, Gustafsson JA, Arner P, Dahlman-Wright K. Impact of estrogen receptor gene polymorphisms and mRNA levels on obesity and lipolysis–a cohort study. BMC Med Genet 2007;8:73.
   PubMed Web of Science ®Google Scholar
• Perneger TV. What’s wrong with Bonferroni adjustments. BMJ 1998;316:1236–1238.
   PubMed Web of Science ®Google Scholar
• Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 2009;10:399–416.
   PubMed Web of Science ®Google Scholar
• Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001;294:853–858.
   PubMed Web of Science ®Google Scholar
• Tsai CJ, Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM, Nussinov R. Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. J Mol Biol 2008;383:281–291.
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315:525–528.
   PubMed Web of Science ®Google Scholar
• Grymek K, Lukasiewicz S, Faron-Góreckaa A, Tworzydlo M, Polit A, Dziedzicka-Wasylewska M. Role of silent polymorphisms within the dopamine D1 receptor associated with schizophrenia on D1-D2 receptor hetero-dimerization. Pharmacol Rep 2009;61:1024–1033.
   PubMed Web of Science ®Google Scholar
• Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest 2008;118:1590–1605.
   PubMed Web of Science ®Google Scholar